Genetic sequences injected into amniotic fluid can treat diseases in utero

Researchers at two U.S. universities have developed a method by which genetic diseases in utero can be treated via an injection into the surrounding fluid. They designed specific genetic sequences to alter the aberrant gene expressions in the fetus.

An interventionist approach such as an injection straight to the fetus can be dangerous and have developmental consequences. But delivering a drug to the amniotic fluid poses much less of a risk and has shown in mouse studied to be effective.

The scientists from Rosalind Franklin University and Oregon Health and Science University engineered short sequences of nucleic acids called antisense oligonucleotides that are designed to bind to specific genes. In the animal studies, when these were injected into the amniotic cavity, mice demonstrated alterations in their gene expression for up to a month after birth.

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

It’s the first of its kind that showed successful embryonic transfer with amniotic administration, according to a release.

“A major barrier to the development of treatments for congenital disorders is the risk to the developing fetus that interventions may pose,” lead author Michelle Hastings of RFU said. “Our demonstration that this promising type of therapeutic can be delivered to the amniotic cavity is an important advance for fetal treatment of disease.”

Read more on

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.